ATI RN
ATI Pharmacology Test Bank Questions
Question 1 of 5
Mark the location of the beginning of the plateau phase on this dose-response relationship curve.
Correct Answer: D
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 2 of 5
A 34-year-old man is a chronic alcoholic and is in and out of a rehabilitation center on a monthly basis. His physician administers a blocker of aldehyde dehydrogenase. Which of the following effects is most likely to be exhibited by this patient following administration?
Correct Answer: D
Rationale: Disulfiram, an aldehyde dehydrogenase blocker, is used in alcoholism to deter drinking. When alcohol is consumed, acetaldehyde accumulates, causing nausea . Bradycardia isn't typical; tachycardia may occur with acetaldehyde buildup. Elation and euphoria contradict the aversive intent. Urticaria (E) is possible but less common. Nausea, with flushing and vomiting, creates an unpleasant reaction, reinforcing abstinence. This aligns with disulfiram's mechanism, leveraging acetaldehyde toxicity to modify behavior, distinguishing it from other effects.
Question 3 of 5
A 33-year-old man with a history of asthma comes into the emergency department after getting stung by a bee. The treating physician wants to give epinephrine subcutaneously. Which of the following contraindications to this medication is noted?
Correct Answer: B
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 4 of 5
A 19-year-old G1P0 woman at 34 weeks gestation lost her eyeglasses for a day. Constant squinting causes her to develop a headache. She asks her doctor for a pain reliever. Which of the following drugs may disrupt her fetus' circulatory system?
Correct Answer: D
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 5 of 5
Which of the following antiparkinsonian drugs may cause vasospasm?
Correct Answer: B
Rationale: Bromocriptine, a dopamine D2 agonist used in Parkinson's, has ergot alkaloid properties, which can cause vasospasm by stimulating vascular smooth muscle receptors, occasionally leading to Raynaud's-like symptoms or digital ischemia. Amantadine, an NMDA antagonist, enhances dopamine release but lacks vasoconstrictive effects. Carbidopa inhibits dopa decarboxylase, aiding levodopa delivery without vascular impact. Entacapone, a COMT inhibitor, extends levodopa's duration but doesn't affect vessels. Ropinirole, a non-ergot agonist, avoids vasospasm. Bromocriptine's ergot-derived vasoconstriction, though rare, distinguishes it among antiparkinsonian drugs, requiring caution in patients with vascular risks.